Literature DB >> 26362999

From DNA Damage to Nucleic Acid Sensing: A Strategy to Enhance Radiation Therapy.

Liufu Deng1, Hua Liang2, Sherry Fu2, Ralph R Weichselbaum2, Yang-Xin Fu3.   

Abstract

Local irradiation (IR) is widely used in the treatment of primary and metastatic tumors. However, the impact of IR on the immune response is currently being defined. Local and distant relapse after radiotherapy often occurs. The current rationale for the use of IR is based on direct cytotoxicity to cancer cells; however, recent studies have shown that reduction of tumor burden following ablative (large-dose) IR largely depends on type I IFN signaling and CD8(+) T-cell response. Here, we review recent findings indicating that antitumor effects of radiation are contributed by both innate and adaptive immune responses. We focus on immune mechanisms, including cytosolic DNA sensing pathways that bridge the traditional view of IR-mediated DNA damage to DNA-sensing immune pathways. Also, we discuss how the efficacy of radiotherapy might be enhanced by targeting nucleic acid-sensing pathways. These findings highlight the mechanisms governing tumor escape from the immune response and the therapeutic potential of synergistic strategies to improve the efficacy of radiotherapy via immunotherapeutic intervention. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26362999     DOI: 10.1158/1078-0432.CCR-14-3110

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  23 in total

Review 1.  Noninvasive PET Imaging of T cells.

Authors:  Weijun Wei; Dawei Jiang; Emily B Ehlerding; Quanyong Luo; Weibo Cai
Journal:  Trends Cancer       Date:  2018-04-17

2.  Bystander Effect Induced by Electroporation is Possibly Mediated by Microvesicles and Dependent on Pulse Amplitude, Repetition Frequency and Cell Type.

Authors:  Ajda Prevc; Apolonija Bedina Zavec; Maja Cemazar; Veronika Kloboves-Prevodnik; Monika Stimac; Vesna Todorovic; Primoz Strojan; Gregor Sersa
Journal:  J Membr Biol       Date:  2016-07-01       Impact factor: 1.843

Review 3.  Targeting innate sensing in the tumor microenvironment to improve immunotherapy.

Authors:  Zhida Liu; Chuanhui Han; Yang-Xin Fu
Journal:  Cell Mol Immunol       Date:  2019-12-16       Impact factor: 11.530

Review 4.  KRAS G12C inhibition and innate immune targeting.

Authors:  Tetsuo Tani; Shunsuke Kitajima; Ella B Conway; Erik H Knelson; David A Barbie
Journal:  Expert Opin Ther Targets       Date:  2021-03-28       Impact factor: 6.902

Review 5.  Functional Interfaces, Biological Pathways, and Regulations of Interferon-Related DNA Damage Resistance Signature (IRDS) Genes.

Authors:  Monikaben Padariya; Alicja Sznarkowska; Sachin Kote; Maria Gómez-Herranz; Sara Mikac; Magdalena Pilch; Javier Alfaro; Robin Fahraeus; Ted Hupp; Umesh Kalathiya
Journal:  Biomolecules       Date:  2021-04-22

Review 6.  Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy.

Authors:  M Michelle Xu; Y Pu; R R Weichselbaum; Y-X Fu
Journal:  Oncogene       Date:  2016-07-18       Impact factor: 9.867

7.  Host STING-dependent MDSC mobilization drives extrinsic radiation resistance.

Authors:  Hua Liang; Liufu Deng; Yuzhu Hou; Xiangjiao Meng; Xiaona Huang; Enyu Rao; Wenxin Zheng; Helena Mauceri; Matthias Mack; Meng Xu; Yang-Xin Fu; Ralph R Weichselbaum
Journal:  Nat Commun       Date:  2017-11-23       Impact factor: 14.919

8.  Radiotherapy to Control Limited Melanoma Progression Following Ipilimumab.

Authors:  Lauren M Kropp; Jennifer F De Los Santos; Svetlana B McKee; Robert M Conry
Journal:  J Immunother       Date:  2016 Nov/Dec       Impact factor: 4.456

9.  Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs.

Authors:  Diana Rose E Ranoa; Akash D Parekh; Sean P Pitroda; Xiaona Huang; Thomas Darga; Anthony C Wong; Lei Huang; Jorge Andrade; Jonathan P Staley; Takashi Satoh; Shizuo Akira; Ralph R Weichselbaum; Nikolai N Khodarev
Journal:  Oncotarget       Date:  2016-05-03

10.  High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers.

Authors:  Michael Hettich; Friederike Braun; Mark D Bartholomä; Reinhold Schirmbeck; Gabriele Niedermann
Journal:  Theranostics       Date:  2016-06-18       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.